Bristol Myers Squibb sets next earnings date, shares trade steadily on NYSE

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-24, 08:02.

Bristol Myers Squibb (US0897961004) prepares for its next quarterly earnings release around late July, with the NYSE-listed shares recently trading in the mid-50 dollar range according to multiple quote services. Consensus expectations for 2026 still reflect cautious optimism on the company’s ability to offset looming patent expirations with new product launches and disciplined capital allocation.

What recent numbers show

Bristol Myers Squibb last reported quarterly figures for the first quarter of 2026, posting earnings that came in above market expectations according to a Seeking Alpha-based analysis summarized by Intellectia. The report highlighted that adjusted earnings per share exceeded consensus estimates, indicating a stronger-than-anticipated start to the year even as revenue growth remained relatively muted in established franchises.

The same analysis noted that Citi lifted its price target on Bristol Myers Squibb to 66 dollars from 64 dollars while reiterating a Neutral rating, underscoring a balanced view between valuation support and pipeline execution risks. According to the article, the market reaction to the Q1 beat was measured, with the shares adding modestly on the day, consistent with the broader S&P 500 healthcare sector response to earnings surprises from large-cap pharma peers such as Pfizer and Merck.

Analyst consensus and dividend signals

Recent aggregated analyst data compiled by Stockscan indicates an average 12-month price target for Bristol Myers Squibb shares of about 61.47 dollars, implying roughly 10 to 11 percent upside from a current price region around 55.50 dollars. The same dataset shows a target range between approximately 58.76 dollars at the low end and 64.17 dollars at the high end, reflecting a spread that captures differing views on the pace at which new therapies can replace expiring blockbusters.

On the capital return side, Bristol Myers Squibb’s board recently affirmed a quarterly dividend of 0.63 dollars per share for its common stock, as reported by Yahoo Finance’s healthcare coverage. The dividend is scheduled to be paid in August 2026 to shareholders of record earlier in the summer, and sits alongside management communication about a pipeline of around 50 compounds and multiple potential launches through 2030 that aim to support cash flows beyond the current patent cycle.

The product portfolio behind the stock

Bristol Myers Squibb generates most of its revenue from prescription medicines in oncology, hematology, cardiovascular and immunology, led historically by products such as the immunotherapy Opdivo and the anticoagulant Eliquis. The company’s pipeline, which management recently described as encompassing about 50 compounds with numerous new medications targeted for launch by 2030, is focused on expanding indications in cancer and autoimmune diseases while adding first-in-class assets.

Where the shares trade today

Bristol Myers Squibb shares (US0897961004) most recently traded on the NYSE at around 55.50 dollars, based on consolidated quote data with a price stamp aligned to late June 2026. This places the market capitalization in the large-cap range for U.S. pharmaceuticals, with the stock forming part of the S&P 500 healthcare cohort alongside peers such as Pfizer and Merck.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. Data and estimates are based on publicly available sources believed to be reliable at the time of writing, but may change without notice.